Atrion Co. (NASDAQ:ATRI) has been assigned a consensus broker rating score of 5.00 (Strong Sell) from the one brokers that provide coverage for the company, Zacks Investment Research reports.
Zacks has also given Atrion an industry rank of 70 out of 255 based on the ratings given to its competitors.
ATRI has been the topic of several analyst reports. ValuEngine upgraded Atrion from a “hold” rating to a “buy” rating in a report on Monday, February 4th. BidaskClub upgraded Atrion from a “hold” rating to a “buy” rating in a report on Friday, February 8th.
The business also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were issued a dividend of $1.35 per share. The ex-dividend date was Thursday, March 14th. This represents a $5.40 annualized dividend and a dividend yield of 0.60%.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Paradigm Financial Advisors LLC purchased a new position in shares of Atrion during the 1st quarter worth $211,000. American Century Companies Inc. raised its holdings in shares of Atrion by 5.8% during the 4th quarter. American Century Companies Inc. now owns 750 shares of the medical instruments supplier’s stock worth $556,000 after acquiring an additional 41 shares during the period. Geode Capital Management LLC raised its holdings in shares of Atrion by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 17,922 shares of the medical instruments supplier’s stock worth $13,281,000 after acquiring an additional 446 shares during the period. Legal & General Group Plc raised its holdings in shares of Atrion by 7.8% during the 4th quarter. Legal & General Group Plc now owns 249 shares of the medical instruments supplier’s stock worth $185,000 after acquiring an additional 18 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Atrion in the 4th quarter valued at about $202,000. Institutional investors and hedge funds own 61.74% of the company’s stock.
Atrion Company Profile
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Read More: What is a stock split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.